A lesson to be learned

International Journal of Tuberculosis and Lung Disease

Volumn 1, Issue 6, 1997, Pages 490-492

  Kanyok, T ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DERIVATIVE; RIFAMPICIN; RIFAPENTINE; TUBERCULOSTATIC AGENT;

CLINICAL TRIAL; DRUG INDUSTRY; HUMAN; MEDICAL ETHICS; NOTE; STANDARD; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; CLINICAL TRIALS; DRUG INDUSTRY; ETHICS, MEDICAL; HUMANS; RIFAMPIN; TUBERCULOSIS;

EID: 0031543712     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Mitchison D A, Ellard G A, Grosset J. New antibacterial drugs for the treatment of mycobacterial diseases in man. Br Med Bull 1988; 44: 757-774.
2. Tam C M, Chan S L, Lam C W, Dickinson J M, Mitchison D A. Bioavailability of Chinese rifapentine during a clinical trial in Hong Kong. Int J Tuberc Lung Dis 1997; 1: 411-416.
3. Personal communication, Abdel Faruqui, Ph.D. Hoecsht Marion Roussel, 1997.
4. The USPHS Study 22 Rifapentine Trial Group, Vernon A, Villarino E, O'Brien R. Relapse with rifampin mono-resistant TB (RMR-TB) in HIV-positive TB patients treated with a once-weekly rifapentine-containing regimen. Int J Tuberc Lung Dis 1997; 1 (Suppl): S51.
5. UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases. Tropical Diseases Research: Progress 1975-94: Highlights 1993-94: Twelfth programme report of the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases. Geneva, WHO 1995.